Pierre Country
    • Homepage
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

Author: Amplia Therapuetics Limited

Posted Date:

March 23, 2026
  • Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

    Amplia Therapuetics Limited
    March 23, 2026
  • Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models

    Amplia Therapuetics Limited
    March 9, 2026
  • Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial

    Amplia Therapuetics Limited
    February 12, 2026
  • Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025

    Amplia Therapuetics Limited
    January 30, 2026
  • NARMAFOTINIB Large-Scale Manufactre Complete

    Amplia Therapuetics Limited
    January 27, 2026